Septerna slumps after scrapping trial of hormonal disorder drug

Septerna

18/02/2025 14:06

** Drug developer Septerna's shares  SEPN.O  fall 66.6% to
$4.49 premarket
    ** Co discontinues an early-stage trial of its experimental
drug for patients with a hormonal disorder called
hypoparathyroidism
    ** In hypoparathyroidism patients, the body does not produce
enough levels of a hormone that regulates calcium and phosphorus
levels in the blood 
    ** SEPN says it stopped the trial after two participants
showed unexpectedly high levels of a substance called
unconjugated bilirubin, which forms when red blood cells break
down
    ** Says it will advance other drugs with distinct and
unrelated chemical structures relative to the discontinued
treatment
    ** Stock has fallen nearly 40% since its Nasdaq debut in
October 

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com;))